[Titration strategy of sacubitril/valsartan in patients with heart failure with reduced ejection fraction and hypotension]

Zhonghua Xin Xue Guan Bing Za Zhi. 2023 Oct 24;51(10):1098-1103. doi: 10.3760/cma.j.cn112148-20221222-01006.
[Article in Chinese]

Abstract

沙库巴曲缬沙坦作为一种新型的血管紧张素受体脑啡肽酶抑制剂,已经成为射血分数降低的心力衰竭(HFrEF)患者的一线用药,同时,沙库巴曲缬沙坦也具有降压作用,所以,目前对于合并低血压的HFrEF(HFrEF-LSBP)患者能否从沙库巴曲缬沙坦中获益存在争议。该文对低血压对沙库巴曲缬沙坦滴定的影响进行综述,并提出了HFrEF-LSBP患者中滴定沙库巴曲缬沙坦的策略,为该类患者的治疗提供参考。.

MeSH terms

  • Aminobutyrates / therapeutic use
  • Angiotensin Receptor Antagonists / therapeutic use
  • Drug Combinations
  • Heart Failure* / drug therapy
  • Humans
  • Hypotension* / drug therapy
  • Stroke Volume
  • Tetrazoles / therapeutic use
  • Treatment Outcome
  • Valsartan / therapeutic use
  • Ventricular Function, Left

Substances

  • sacubitril
  • Valsartan
  • Aminobutyrates
  • Drug Combinations
  • Angiotensin Receptor Antagonists
  • Tetrazoles